Introduction {#section5-1178223420906428}
============

Worldwide, breast cancer (BC) is the most prevalent and the first leading cause of cancer death among females. Breast cancer represents 24.2% of all cancers in women and about 11.6% of all new cancer cases.^[@bibr1-1178223420906428]^ In 2018, the World Health Organization (WHO) has estimated that more than 630 000 women died due to BC.^[@bibr1-1178223420906428]^

Triple-negative breast cancer (TNBC) is an aggressive tumor form accounting for approximately 15% to 20% of all BC cases.^[@bibr2-1178223420906428]^ This subtype is defined pathologically by the absence of expression of the estrogen receptor (ER) and progesterone receptor (PgR) and does not exhibit amplification of the human epidermal growth factor receptor 2 gene (HER2).^[@bibr3-1178223420906428]^

Triple-negative breast cancer is a highly heterogeneous form of BC. This subtype is characterized by diagnosis at a younger age, larger tumor size, high-tumor grade, high mitotic index, and higher rate of mortality.^[@bibr4-1178223420906428],[@bibr5-1178223420906428]^ Moreover, it is widely reported that TNBC constitutes an aggressive BC subtype because it is usually associated with a high frequency of metastasis with distinct metastatic patterns and a relatively high recurrence rate and it is usually accompanied by a significant decrease in overall survival (OAS).^[@bibr6-1178223420906428]^ Patients with TNBC are more likely to experience relapse within the first 3 years and are at high risk of death in the first 5 years following diagnosis.^[@bibr7-1178223420906428]^

In Morocco, data from different oncology centers converge toward its characterization as an aggressive form that occurs at a young age and poses a real health problem.^[@bibr7-1178223420906428][@bibr8-1178223420906428][@bibr9-1178223420906428]-[@bibr10-1178223420906428]^ This retrospective study was planned to investigate epidemiological and clinicopathological characteristics, treatment outcome, and survival rate in a Moroccan population with TNBC and to compare them with non-TNBC cases.

Methods {#section6-1178223420906428}
=======

Study design and population {#section7-1178223420906428}
---------------------------

This retrospective study was conducted in the National Institute of Oncology in Rabat, Morocco. A total of 905 BC cases diagnosed in 2009 and followed up until 2014 were included in the study. For each patient, the medical record was carefully reviewed to obtain information regarding clinical, pathological, and therapeutic characteristics. A total of 405 cases with missed data, foreign people, and men patients were excluded and the remaining 500 BC cases were divided according to their molecular subtype into 2 groups: 85 patients with TNBC in group 1 (G1) and 415 non-TNBC patients in group 2 (G2).

The study was conducted concerning legal aspects and was approved by the Ethical Committee of Biological Research, Faculty of Medicine and Pharmacy---Rabat.

Data collection {#section8-1178223420906428}
---------------

Data were recorded from patients' medical files. The medical records were retrospectively reviewed and information regarding age, anthropometry measurement (weight and height), familial history of BC, hormonal status, clinical data, cancer stage, tumor size, histological type, tumor grade, lymph node involvement, metastases, hormonal receptors, treatment (surgery, chemotherapy, radiation therapy, hormonal therapy), and follow-up was collected using SPSS software.

The histological type was recorded and updated according to the latest WHO classification of breast tumors.^[@bibr11-1178223420906428]^ Pathological tumor-node-metastasis (pTNM) staging was done according to the TNM classification of the seventh edition of the American Joint Committee on Cancer (AJCC) classification.^[@bibr12-1178223420906428]^ Histological tumor grading was evaluated according to Scarff-Bloom and Richardson (SBR) grading system modified by Singletary et al,^[@bibr13-1178223420906428]^ and vascular invasion was quantified histologically.

Immunohistochemical analysis was used to determine ER and PgR status and was performed using standard procedures on 4-μm sections of paraffin-embedded tissue specimens stained with the monoclonal antibodies 6F11 and 1A6, respectively. Accordingly, ER and PgR were considered positive when the nuclear expression was observed in at least 10% of the tumor cells.^[@bibr12-1178223420906428]^

Immunohistochemical expression of Her2 was evaluated according to cytoplasmic membrane staining of the infiltrative component, concerning the intensity and the percentage of stained cells and taking into account the complete or incomplete membrane staining. Results are expressed in scores: 0/1+ for negative, 2+ for ambiguous, and 3+ for positive staining. Fluorescent in situ hybridization (FISH) was performed to assess Her2 amplification when the score was ambiguous. Accordingly, if the Her2 amplification is confirmed by FISH, the case was considered HER2 positive.^[@bibr12-1178223420906428]^

Follow-up {#section9-1178223420906428}
---------

Patients were followed up until December 2014. Event-free survival (EFS) was calculated from the date of surgery or the date of starting the first course of chemotherapy to the date of loco-regional recurrence or distant metastasis.

Statistical analysis {#section10-1178223420906428}
--------------------

Statistical analysis was performed using SPSS software version 13.0 (IBM, Armonk, NY, USA). Descriptive variables were expressed as mean ± SD or median (interquartile range). Differences between qualitative data were assessed using the chi-square test. Survival rate calculation was performed by the Kaplan-Meier method and compared using the log-rank test.

Univariate and multivariate Cox regression model was performed to compare variables and outcomes. The difference is considered significant if the *P* value is *\<*.05. In the multivariate model, all parameters reported in previous studies to influence survival rates were included even if these parameters were not significant in the univariate model of this study.

Results {#section11-1178223420906428}
=======

Clinicopathological characteristics {#section12-1178223420906428}
-----------------------------------

Concerning inclusion/exclusion criteria, 17% of BC cases registered at the National Institute of Oncology in Rabat have a TNBC (85/500). Clinical and pathological data are reported, respectively, in [Tables 1](#table1-1178223420906428){ref-type="table"} and [2](#table2-1178223420906428){ref-type="table"}.

###### 

Comparative clinical data.

![](10.1177_1178223420906428-table1)

  Variables                                    All patients, %   TNBC, %     Non-TNBC, %   *P* value
  -------------------------------------------- ----------------- ----------- ------------- -----------
  Nulliparity at diagnosis                                                                 
   Yes                                         89 (22.7)         14 (20.0)   75 (23.3)     .638
   No                                          303 (77.3)        56 (80.0)   247 (76.7)    
  Number of cases with full-term pregnancies                                               
   0                                           89 (22.6)         14 (20.0)   75 (23.2)     .003
   1                                           43 (10.9)         14 (20.0)   29 (9.0)      
   2-4                                         131 (33.3)        13 (18.6)   118 (36.5)    
   ⩾5                                          130 (33.1)        29 (41.4)   101 (31.3)    
  Oral contraception use                                                                   
   Yes                                         127 (42.2)        25 (50.0)   102 (40.6)    .272
   No                                          174 (57.8)        25 (50.0)   149 (59.4)    
  Menopausal status                                                                        
   Yes                                         159 (40.3)        37 (51.4)   122 (37.8)    .035
   No                                          236 (59.7)        35 (48.6)   201 (62.2)    
  Familial history of BC                                                                   
   Yes                                         54 (14.7)         10 (14.9)   44 (14.7)     1.000
   No                                          313 (85.3)        57 (85.1)   256 (85.3)    
  Clinical signs                                                                           
   Yes                                         45 (10.5)         10 (13.2)   35 (10.0)     ---
   No                                          382 (89.5)        66 (86.8)   316 (90.0)    
  Age                                                                                      
   \<50                                        249 (58.6)        41 (54.7)   208 (59.4)    .519
   ⩾50                                         176 (41.4)        34 (45.3)   142 (40.6)    
  Age at menarche                                                                          
   ⩽12                                         33 (33)           4 (28.6)    29 (33.7)     .873
   13-14                                       43 (43)           6 (42.9)    37 (43.0)     
   ⩾15                                         24 (24)           4 (28.6)    20 (23.3)     
  Breast side                                                                              
   Right                                       209 (49.2)        33 (44.0)   176 (50.3)    .373
   Left                                        216 (50.8)        42 (56.0)   174 (49.7)    
  Body mass index                                                                          
   Thinness                                    6 (2.2)           1 (1.9)     5 (2.3)       .056
   Normal weight                               90 (33.1)         10 (18.9)   80 (36.5)     
   Overweight                                  99 (36.4)         26 (49.1)   73 (33.3)     
   Obesity                                     77 (28.3)         16 (30.2)   61 (27.9)     

Abbreviation: TNBC, triple-negative breast cancer.

###### 

Comparative pathological data by TNBC groups.

![](10.1177_1178223420906428-table2)

  Variables                All patients, %   TNBC, %     Non-TNBC, %   *P* value
  ------------------------ ----------------- ----------- ------------- -----------
  Tumor size                                                           
   T1                      88 (23.2)         11 (18.3)   77 (24.1)     .154
   T2                      207 (54.5)        30 (50.0)   177 (55.3)    
   T3                      85 (22.4)         19 (31.7)   66 (20.6)     
  Lymph nodes                                                          
   N0                      153 (39.8)        30 (51.7)   123 (37.7)    .164
   N1                      109 (28.4)        16 (27.6)   93 (28.5)     
   N2                      65 (16.9)         6 (10.3)    59 (18.1)     
   N3                      57 (14.8)         6 (10.3)    51 (15.6)     
  Intraductal components                                               
   Yes                     183 (52.6)        17 (30.9)   166 (56.7)    .001
   No                      165 (47.4)        38 (69.1)   127 (43.3)    
  Vascular invasion                                                    
   Yes                     151 (39.8)        17 (27.4)   134 (42.3)    .033
   No                      228 (60.2)        45 (72.6)   183 (57.7)    
  SBR grade                                                            
   SBR I                   29 (7.3)          3 (4.6)     26 (7.8)      .001
   SBR II                  230 (57.8)        26 (40.0)   204 (61.3)    
   SBR III                 139 (34)          36 (55.4)   103 (30.9)    

Abbreviations: N, nodes; SBR, Scarff-Bloom and Richardson classification; TNBC, triple-negative breast cancer.

A complete database is given as an [online suppelmantary file](http://journals.sagepub.com/doi/suppl/10.1177/1178223420906428). Overall, the median age at diagnosis of TNBC cases was 47 ± 11.75, with extreme ages at 40 and 55 years. Only 14.9% of the cases have a familial history of BC. In this study, TNBC and non-TNBC cases shared the same distribution regarding clinical data.

A comparison between TNBC and non-TNBC cases showed a statistically significant difference for the number of full-term pregnancies (*P* = .003) and menopausal status (*P* = .035). A total of 41.4% of TNBC cases have more than 4 children as compared with non-TNBC cases. Moreover, 51.4% of TNBC cases (37/72) and only 37.8% of non-TNBC cases (122/323) are menopausal. The other parameters, including age, age at menarche, nulliparity at diagnosis, oral contraception use, and anthropometric data, did not show statistically significant differences between TNBC and non-TNBC cases.

The pathological characteristics of TNBC cases clearly show the predominance of N0 lymph node status and SBR grade III.

Comparison between TNBC and non-TNBC cases showed significant differences regarding intraductal components (*P* = .001), SBR grade (*P* = .001), and vascular invasion (*P* = .033).

Treatment {#section13-1178223420906428}
---------

Patients with TNBC and non-TNBC received the same treatments as no specific treatment is recommended for TNBC cases; hormonal and Herceptin treatments are exclusively given to patients with positive hormone and Her2 receptors. Comparative treatment data between TNBC and non-TNBC cases are summarized in [Table 3](#table3-1178223420906428){ref-type="table"}. Statistical analysis did not show any significant difference for the 4 treatment modalities.

###### 

Comparative treatment data by TNBC groups.

![](10.1177_1178223420906428-table3)

  Variables                  All patients, %   TNBC, %     Non-TNBC, %   *P* value
  -------------------------- ----------------- ----------- ------------- -----------
  Neoadjuvant chemotherapy                                               
   Yes                       76 (19.1)         20 (26.3)   56 (17.4)     .104
   No                        321 (80.9)        56 (73.7)   265 (82.6)    
  Adjuvant chemotherapy                                                  
   Yes                       322 (79.1)        55 (76.4)   267 (79.7)    .632
   No                        85 (20.9)         17 (23.6)   68 (20.3)     
  Radiotherapy                                                           
   Yes                       276 (64.8)        50 (65.8)   226 (64.6)    .895
   No                        150 (35.2)        26 (34.2)   124 (35.4)    
  Surgery                                                                
   Tumorectomy               95 (23.5)         20 (29.4)   75 (22.3)     .213
   Mastectomy                309 (76.5)        48 (70.6)   261 (77.7)    
  Hormone therapy                                                        
   Yes                       ---               ---         273 (65.8)    ---
   No                        ---               ---         142 (34.2)    

Abbreviation: TNBC, triple-negative breast cancer.

Analysis of EFS {#section14-1178223420906428}
---------------

The estimated median follow-up period was 30 ± 21.28 (10-53) months with extreme ranges of 3 to 67 months. Event-free survival was calculated using univariate analysis by Kaplan-Meier method and results are reported in [Figure 1](#fig1-1178223420906428){ref-type="fig"}. The 3-year EFS of patients with the local disease was 76% and 83% of women with TNBC and non-TNBC, respectively. After 5 years, the EFS was higher in patients with TNBC (73%) than in patients with non-TNBC (65%). The difference between EFS in TNBC and non-TNBC patients is not statistically significant (*P* = .42). Results of EFS correlation to some relevant parameters are represented in [Figures 2](#fig2-1178223420906428){ref-type="fig"} and [3](#fig3-1178223420906428){ref-type="fig"}. Event-free survival is poorer in TNBC women with N3 lymph nodes (*P* = .00). In non-TNBC women, EFS is better in patients with N3 lymph nodes (*P* = .00).

![Event-free survival (EFS) in TNBC/non-TNBC patients with local disease. TNBC indicates triple-negative breast cancer.](10.1177_1178223420906428-fig1){#fig1-1178223420906428}

![Event-free survival correlated to lymph nodes, lymphovascular invasion, neoadjuvant chemotherapy, adjuvant chemotherapy, and radiotherapy in TNBC group. TNBC indicates triple-negative breast cancer.](10.1177_1178223420906428-fig2){#fig2-1178223420906428}

![Event-free survival correlated to lymph nodes, lymphovascular invasion, neoadjuvant chemotherapy, adjuvant chemotherapy, and radiotherapy in non-TNBC group. TNBC indicates triple-negative breast cancer.](10.1177_1178223420906428-fig3){#fig3-1178223420906428}

Univariate and multivariate Cox regression analysis {#section15-1178223420906428}
---------------------------------------------------

The results of univariate and multivariate Cox regression analyses are reported in [Table 4](#table4-1178223420906428){ref-type="table"}. Univariate analysis indicated that N3 lymph node, chemotherapy, and radiotherapy are statistically significant parameters influencing EFS in women with TNBC.

###### 

Univariate and multivariate Cox regression analysis for event-free survival (EFS).

![](10.1177_1178223420906428-table4)

  Variables                  TNBC    Non-TNBC                                                                                     
  -------------------------- ------- ------------- ------ ------- --------- ------ ------ ------------ ------ ------ ------------ ------
  Nulliparity                                                                                                                     
   No                        1                            1                        1                                              
   Yes                       1.54    0.32-7.84     0.59   0.16    0.00-\>   0.94   1.20   0.63-2.28    0.57                       
  OC use                                                                                                                          
   No                        1                            1                        1                                              
   Yes                       0.01    0.00-6.23     0.17   0.01    0.00-\>   0.61   1.01   0.51-2.00    0.95                       
  FHBC                                                                                                                            
   No                        1                            1                        1                                              
   Yes                       2.01    0.41-9.76     0.38   19.55   0.00-\>   0.90   1.01   0.43-2.40    0.96                       
  Obesity                                                                                                                         
   No                        1                            1                        1                                              
   Yes                       0.02    0.00-6.86     0.19   1.43    0.00-\>   0.98   1.23   0.61-2.45    0.55                       
  IBC                                                                                                                             
   No                        1                                                     1                          1                   
   Yes                       2.43    0.52-11.28    0.25                            2.66   1.24-5.70    0.01   0.65   1.19-2.26    0.50
  Tumor size, mm                                                                                                                  
   ⩽20                       1                                                     1                                              
   21-50                     \>      0.00-\>       0.94                            1.41   0.60-3.30    0.42                       
   \>50                      \>      0.00-\>       0.94                            2.25   0.89-5.72    0.08                       
  SBR grade                                                                                                                       
   I                         1                                                     1                                              
   II                        \>      0.00-\>       0.95                            2.36   0.31-17.58   0.40                       
   III                       \>      0.00-\>       0.96                            5.97   0.80-44.16   0.80                       
  N status                                                                                                                        
   N0                        1                            1                        1                          1                   
   N1                        0.9     0.08-10.14    0.94   5.87    0.00-\>   0.95   1.33   0.54-3.29    0.52   1.29   0.47-3.49    0.61
   N2                        2.41    0.21-26.72    0.47   0.65    0.00-\>   0.99   3.34   1.38-8.09    0.00   2.43   0.89-6.63    0.08
   N3                        18.46   2.76-123.26   0.00   1.54    0.00-\>   0.99   5.19   2.29-11.76   0.00   3.71   1.35-10.21   0.01
  LVI                                                                                                                             
   No                        1                            1                        1                          1                   
   Yes                       3.54    0.94-13.26    0.06   28.86   0.00-\>   0.90   1.83   1.01-3.32    0.04   1.12   1.07-4.20    0.03
  Surgery type                                                                                                                    
   Radical mastectomy        1                                                     1                                              
   Conserving surgery        0.57    0.12-2.73     0.48                            0.62   0.27-1.39    0.24                       
  Radiotherapy                                                                                                                    
   No                        1                            1                        1                          1                   
   Yes                       0.02    0.00-1.13     0.00   0.00    0.00-\>   0.91   0.38   0.22-0.68    0.00   0.44   0.21-0.93    0.03
  Neoadjuvant chemotherapy                                                                                                        
   No                        1                            1                        1                          1                   
   Yes                       10.12   3.00-34.14    0.00   30.11   0.00-\>   0.89   3.10   1.66-5.81    0.00   1.76   0.51-6.09    1.76
  Adjuvant chemotherapy                                                                                                           
   No                        1                            1                        1                          1                   
   Yes                       0.17    0.05-0.59     0.00   93.55   0.00-\>   0.90   0.32   0.17-0.59    0.00   0.46   0.18-1.16    1.10
  Trastuzumab                                                                                                                     
   No                        ---     ---           ---    ---     ---       ---    1                                              
   Yes                       ---     ---           ---    ---     ---       ---    0.65   0.25-1.63    0.36                       
  Hormone therapy                                                                                                                 
   No                        ---     ---           ---    ---     ---       ---    1                          1                   
   Yes                       ---     ---           ---    ---     ---       ---    0.20   1.11-0.36    0.00   0.23   0.11-0.48    0.00

Abbreviations: CI, confidence interval; FHBC: family history of breast cancer; HR, hazard ratio; IBC, inflammatory breast cancer; SBR: Scarff-Bloom and Richardson classification; TNBC, triple-negative breast cancer.

Univariate analysis showed that, among non-TNBC cases, inflammatory BC, N2 and N3 status, presence of vascular invasion, radiotherapy, chemotherapy, and hormone therapy are associated with poorer EFS.

Concerning N3 lymph node status, the risk of relapse is higher in the TNBC group (18.46; *P* = .001) as compared with the non-TNBC group (5.19; *P* = .001). Of particular interest, the administration of neoadjuvant chemotherapy is a risk factor for both TNBC group (10.12, 3.00-34.14; *P* = .001) and non-TNBC group (3.10, 1.66-5.81; *P* = .001). However, adjuvant chemotherapy was beneficial for progression-free survival. In fact, the relapse risk was lower, corresponding to 0.17 (*P* = .005) for patients with TNBC and 0.32 (*P* = .001) for non-TNBC patients. For radiotherapy, the risk of relapse was lower for both TNBC and non-TNBC patients, with 0.024 (*P* = .001) and 0.38 (*P* = .001), respectively. For non-TNBC group, the risk of relapse after hormone therapy was 0.20 (*P* = .001).

Multivariate analysis showed no statistically significant results for TNBC cases. However, in non-TNBC cases, the multivariate analysis highlighted the same results than the univariate analysis regarding N3 status, presence of vascular invasion, radiotherapy, and hormone therapy.

Discussion {#section16-1178223420906428}
==========

Worldwide, epidemiological and clinical data clearly showed that TNBC is an aggressive form of BC and is associated with a poor prognosis and a low EFS rising on a great challenge in the global management of BC. In Morocco, limited data on TNBC are available and studies were conducted on small size series.^[@bibr7-1178223420906428],[@bibr8-1178223420906428],[@bibr10-1178223420906428]^ Therefore, this study was planned to be a large one to assess the epidemiology profile, tumor characteristics, and treatment patterns of TNBC cases compared with non-TNBC cases recruited in the National Institute of Oncology (INO) in Rabat. National Institute of Oncology is considered as the reference public health oncology center in Morocco and receives patients from the whole country.

In this study, TNBC was reported in 17% of BC cases, which is comparable to previously reported data in Morocco.^[@bibr7-1178223420906428],[@bibr8-1178223420906428],[@bibr10-1178223420906428]^ [Table 5](#table5-1178223420906428){ref-type="table"} reports the prevalence of TNBC in Morocco as compared with other North African countries and some sub-Saharan, European, American, and Asian countries.

###### 

Comparison of TNBC frequencies.

![](10.1177_1178223420906428-table5)

  Region of the world      Frequency of TNBC, %   Country               Study
  ------------------------ ---------------------- --------------------- ---------------------------------------------
  Maghreb (North Africa)   17                     Morocco               This Study
                           22.5                   Tunisia               Fourati et al^[@bibr14-1178223420906428]^
                           19.77                  Algeria               Gaceb et al^[@bibr15-1178223420906428]^
                           18                     Tunisia               Der et al^[@bibr16-1178223420906428]^
  Sub-Saharan Africa       82                     Ghana                 Der et al^[@bibr16-1178223420906428]^
                           46                     Mali                  Ly et al^[@bibr17-1178223420906428]^
                           44                     Kenya                 Der et al^[@bibr16-1178223420906428]^
                           36                     Uganda                Der et al^[@bibr16-1178223420906428]^
                           32                     Kenya                 Der et al^[@bibr16-1178223420906428]^
                           27                     Nigeria and Senegal   Der et al^[@bibr16-1178223420906428]^
                           23                     Kenya                 Der et al^[@bibr16-1178223420906428]^
                           15.9                   Sudan                 Der et al^[@bibr16-1178223420906428]^
  Europe                   11                     Italy                 Minicozzi et al^[@bibr18-1178223420906428]^
  USA                      23.7                   African Americans     Plasilova et al^[@bibr19-1178223420906428]^
  Asia                     29.8                   India                 Der et al^[@bibr16-1178223420906428]^
                           25                     India                 Der et al^[@bibr16-1178223420906428]^
                           21                     Indonesia             Der et al^[@bibr16-1178223420906428]^
                           17.6                   Malaysia              Der et al^[@bibr16-1178223420906428]^
                           15                     Malaysia              Der et al^[@bibr16-1178223420906428]^
                           12.9                   Chínese               Su et al^[@bibr20-1178223420906428]^
                           8.9                    Philippines           Plasilova et al^[@bibr19-1178223420906428]^

Abbreviation: TNBC, triple-negative breast cancer.

Triple-negative breast cancer prevalence in Morocco is in agreement with obtained data in the other North African countries (Algeria and Tunisia) and much lower than almost sub-Saharan countries. These results highlight the high prevalence of TNBC in sub-Saharan countries that could be due to some genetic factors or attributed to some technical limitations leading to an overestimation of false-positive/negative results in performing and interoperating immunohistochemistry analysis related to ER, PR, and Her2 expression.

Triple-negative breast cancer is a complex and heterogeneous BC subtype associated with clinical, pathological, and biological factors highly variable according to the population. In our study, nulliparity at diagnosis is significantly less frequent in women with TNBC than in women with non-TNBC, and TNBC cases are more obese. These results are in agreement with recent studies reported by Plasilova et al,^[@bibr19-1178223420906428]^ showing that the risk for developing TNBC rises with increasing parity and increasing the waist-to-hip ratio circumference, suggesting a complex interaction of genetic biomarkers and societal factors.

Triple-negative breast cancer and patients' age are well studied and discussed. Some results showed that in all ethnic/racial groups, the incidence of TNBC increased among young patients.^[@bibr21-1178223420906428],[@bibr22-1178223420906428]^ In the United States, Plasilova et al^[@bibr19-1178223420906428]^ have reported that in white patients, TNBC prevails in patients below age 40, whereas in black patients, the incidence of TNBC is still higher until age 60. Of particular interest, the age of BC onset is 10 years earlier than in Western countries.^[@bibr2-1178223420906428]^ This finding is in agreement with previous studies in patients with TNBC from Tunisia.^[@bibr15-1178223420906428]^ A recent study conducted in Morocco highlighted the high frequency of BC in young women as compared with Western countries.^[@bibr23-1178223420906428]^ In this study, both TNBC and non-TNBC cases prevail in younger women, with no statistical difference between the 2 groups.

Worldwide, published data show that TNBC cases are characterized by bigger tumor sizes and high-grade histology.^[@bibr24-1178223420906428],[@bibr25-1178223420906428]^ Regarding tumor size, there is no statistical difference between TNBC and non-TNBC groups in this study. Of particular interest, Dent et al^[@bibr26-1178223420906428]^ have conducted a long-term follow-up of 1608 patients with BC and found that the recurrence of TNBC did not correlate with the tumor size.

The association between lymph node status and TNBC is controversial. Some authors report that lymph node negativity is more frequent in TNBC.^[@bibr27-1178223420906428]^ Others support a higher frequency of lymph node positivity^[@bibr28-1178223420906428]^ and this lymph node positivity is associated with a poor prognosis,^[@bibr24-1178223420906428]^ whereas some publications suggest the absence of any association between increased tumor diameter and lymph node metastasis.^[@bibr28-1178223420906428],[@bibr29-1178223420906428]^ In this study, most of the TNBC cases exhibit an SBR grade III as compared with non-TNBC cases (55.4% vs 30.9%). Large tumors and high SBR grade are in favor of a high lymph node metastases incidence. However, after adjustment of these factors, the incidence of positive nodes with TNBC is considerably less than non-TNBC, which is in agreement with previously reported data.^[@bibr7-1178223420906428],[@bibr19-1178223420906428],[@bibr30-1178223420906428]^ Conversely, some other studies show that there is no statistical correlation of lymph nodes status between TNBC and non-TNBC groups.^[@bibr5-1178223420906428],[@bibr14-1178223420906428]^

Triple-negative breast cancer is unresponsive to endocrine therapy, and currently, chemotherapy is the main option for systemic treatment of women with TNBC. In our study, the most of the TNBC and non-TNBC patients received systemic chemotherapy. Moreover, the odds of receiving chemotherapy were much greater for TNBC than for non-TNBC cases, even when adjusted for stage and grade. Furthermore, TNBC cases were more likely to receive neoadjuvant chemotherapy treatment.

As already reported widely,^[@bibr31-1178223420906428],[@bibr32-1178223420906428]^ TNBC was significantly associated with poorer EFS, mainly because of the inability to administer hormone therapy to this BC subtype.

This study is very informative highlighting the main characteristics of TNBC cases in our population. The main limitations of the study are as follows: (1) the absence of a date of death in the medical records, which limited the calculation of the OAS, and (2) the noncomplete data in some patients' files records that could have influenced the analysis.

Conclusions {#section17-1178223420906428}
===========

Understanding the pathogenesis of TNBC and molecular and immunological characteristics of the disease is the key for better management of this heterogeneous disease. Clinical data highlighted that TNBC have the worse outcome compared with the non-TNBC. Moreover, common risk factors including age, premenopausal status, increased parity, hormonal contraceptive use, high histologic grade, and advanced disease were independently associated with TNBC.

Nowadays, many promising therapeutic pathways are investigated, but without a comprehensive consideration of TNBC pathogenesis, predicting the effectiveness of these strategies will be compromised.
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